Presented by Biovays…

• The big news of the day was Amylin Pharmaceuticals (AMLN). AMLN finally had its annual shareholder meeting and based off early results, it looks like the company will lose at least two board seats to Carl Icahn and Eastbourne Capital Management LLC. [Bloomberg]

• Cougar Biotechnology shows off its prostate cancer drug abiraterone; shrinks tumors in 2/3 men. [Reuters]

• FDA to Drugmakers: don’t hide drug side effects in the middle of an ad, put them at the beginning or end. [WSJ Health Blog]

• A lawsuit against Pfizer was dismissed, alleged company falsified Lipitor claims to boost sales. [Bloomberg]

• What’s this??!! Teva the one suing???!! [The Globe and Mail]

• FDA turns down Allergan’s application to market Botox for upper limb spasticity. [Motley Fool]

• Spectrum Pharmaceuticals raises $20M from institutional investors. [BioSpace]

• CombinatoRx diabetes data sends stock up almost 40%. [Reuters]

• Finally, the FDA has extended the review timeline for J&J, Centocor’s psoriasis drug – Stelara (ustekinumab). [Pharmaceutical Business Review]

Anonymous Tip? Comments? Contact us at: hr@iguanabio.com

Image from maximumpc

Related Posts